CELLSENSE - MICROENGINEERING CELL RESPONSE
Our CellSense technology is designed to interfere with the complex biological response involved in the foreign body reaction and subsequent formation of fibrotic tissue around the implantable medical device.
It comprises surface micro-engineered bio-synthesized cellulose which disrupts the process of cell adhesion and deposition of fibrous tissue, through a combination of rationally designed physio-chemical and surface characteristics.
The foreign body response begins with adsorption of various proteins to the surface of the implant. This non-specific layer of proteins labels the device as foreign to the body and triggers high neutrophil activity and release of soluble factors.
Subsequently macrophages and monocyte precursor cells are recruited. Given the impossibility to kill the foreign object, the immune system starts the recruitment of fibroblasts, with the aim of encapsulating the foreign material in a newly deposited collagen matrix. The resulting fibrotic capsule creates a thick physical and physiological barrier between the implant and the host tissue, leading to several clinical problems.
The CellSense technology is the foundation for Hylomate. Extensive R&D has been undertaken to gather evidence on its safety and performance in vitro and in vivo, and these endeavors have been published in a number of peer-reviewed scientific journals.
In vitro studies have shown the reliability of the production process as well as the effectiveness of the technology to significantly reduce the inflammatory process when compared to other materials and surfaces [1-2].
Long term in vivo studies have shown a significant reduction of foreign body reaction and fibrotic encapsulation when combined with a variety of implantable medical devices .
 S. Bottan et al., “Surface-structured bacterial cellulose with guided assembly-based biolithography (GAB),” ACS Nano, vol. 9, no. 1, pp. 206–219, 2015.
 F. Robotti et al., “A micron-scale surface topography design reducing cell adhesion to implanted materials,” Sci. Rep., vol. 8, no. 1, p. 10887, Dec. 2018.
 F. Robotti et al, "Microengineered biosynthesized cellulose as anti-ﬁbrotic in vivo protection for cardiac implantable electronic devices," Biomaterials, vol. 229, 2020.